Cargando…

MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias

CXCR4 is a negative prognostic marker in acute myeloid leukemias (AMLs). Therefore, it is necessary to develop novel ways to inhibit CXCR4 expression in leukemia. AMD3100 is an inhibitor of CXCR4 currently used to mobilize cancer cells. CXCR4 is a target of microRNA (miR)-146a that may represent a n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spinello, I, Quaranta, M T, Riccioni, R, Riti, V, Pasquini, L, Boe, A, Pelosi, E, Vitale, A, Foà, R, Testa, U, Labbaye, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255264/ https://www.ncbi.nlm.nih.gov/pubmed/22829170 http://dx.doi.org/10.1038/bcj.2011.24

Ejemplares similares

AMD3100/CXCR4 Inhibitor
por: De Clercq, Erik
Publicado: (2015)

CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
por: Nishimura, Yukihide, et al.
Publicado: (2011)

The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells
por: Spinello, Isabella, et al.
Publicado: (2019)

CXCR4 Antagonist AMD3100 Modulates Claudin Expression and Intestinal Barrier Function in Experimental Colitis
por: Xia, Xian-Ming, et al.
Publicado: (2011)

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro
por: Kim, Ha-Yon, et al.
Publicado: (2010)

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo
por: Yu, M, et al.
Publicado: (2011)

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
por: Broxmeyer, Hal E., et al.
Publicado: (2005)

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation
por: Zhou, Jun, et al.
Publicado: (2020)

Inhibition of CXCR4 in Spinal Cord and DRG with AMD3100 Attenuates Colon-Bladder Cross-Organ Sensitization
por: Zhang, Hengshuai, et al.
Publicado: (2022)

Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells
por: Paolillo, Rosa, et al.
Publicado: (2015)

Synthesis and Evaluation of [(67)Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4
por: Aghanejad, Ayuob, et al.
Publicado: (2014)

Advances in Understanding the Links between Metabolism and Autophagy in Acute Myeloid Leukemia: From Biology to Therapeutic Targeting
por: Saulle, Ernestina, et al.
Publicado: (2023)

Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model
por: Kang, Yubin, et al.
Publicado: (2010)

CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats
por: Mason, Briana, et al.
Publicado: (2021)

miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development
por: Testa, Ugo, et al.
Publicado: (2017)

The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Wang, Shan, et al.
Publicado: (2020)

Targeting CXCL12/CXCR4 Signaling with AMD3100 Might Selectively Suppress CXCR4+ T-Cell Chemotaxis Leading to the Alleviation of Chronic Prostatitis
por: Zhang, Meng, et al.
Publicado: (2022)

Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells
por: Saulle, Ernestina, et al.
Publicado: (2021)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100
por: Maeda, Yosuke, et al.
Publicado: (2014)

MOBILIZATION STUDIES IN COMPLEMENT-DEFICIENT MICE REVEAL THAT OPTIMAL AMD3100 MOBILIZATION OF HEMATOPOIETIC STEM CELLS DEPENDS ON COMPLEMENT CASCADE ACTIVATION BY AMD3100-STIMULATED GRANULOCYTES
por: Lee, HakMo, et al.
Publicado: (2009)

HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration, and invasion in lung cancer
por: Muralidharan, Ranganayaki, et al.
Publicado: (2015)

CXCR4 antagonist AMD3100 elicits analgesic effect and restores the GlyRα3 expression against neuropathic pain
por: Liu, Xiaoming, et al.
Publicado: (2017)

Comparison of the Response to the CXCR4 Antagonist AMD3100 during the Development of Retinal Organoids Derived from ES Cells and Zebrafish Retina
por: Wu, Yihui, et al.
Publicado: (2022)

The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer
por: Labbaye, Catherine, et al.
Publicado: (2012)

AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome
por: McDermott, David H, et al.
Publicado: (2011)

The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
por: Berning, Philipp, et al.
Publicado: (2018)

Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13
por: Li, Pengcui, et al.
Publicado: (2016)

CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation
por: Ullah, Aftab, et al.
Publicado: (2019)

Combinatorial G-CSF/AMD3100 Treatment in Cardiac Repair after Myocardial Infarction
por: Rüder, Constantin, et al.
Publicado: (2014)

Treatment with AMD3100 attenuates the microglial response and improves outcome after experimental stroke
por: Walter, Helene L, et al.
Publicado: (2015)

VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
por: Meeson, Richard, et al.
Publicado: (2018)

Alpha-tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation combined injury in mice
por: Singh, Vijay K., et al.
Publicado: (2014)

AMD3100 inhibits the migration and differentiation of neural stem cells after spinal cord injury
por: Liu, Jia-Ming, et al.
Publicado: (2017)

Functional Phenotypes of Peritoneal Macrophages Upon AMD3100 Treatment During Colitis-Associated Tumorigenesis
por: Wu, Shuai, et al.
Publicado: (2022)

Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice
por: Liu, Tao, et al.
Publicado: (2016)

AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments
por: LIAO, YU-XIN, et al.
Publicado: (2015)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
por: Rios, Adan, et al.
Publicado: (2016)

[(18)F]DPA-714 PET Imaging of AMD3100 Treatment in a Mouse Model of Stroke
por: Wang, Yu, et al.
Publicado: (2014)

AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem/progenitor cells
por: Im, Jin Young, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6gem7hqef30prhepd1l8104fkc